Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 13/20 | 0.37 |
| ▸ | JAK3 | P52333 | 6/20 | 0.37 |
| ▸ | JAK2 | O60674 | 5/20 | 0.36 |
| ▸ | JAK1 | P23458 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1369238 | 0.85 | JAK3 (0.38) | SYKJAK3JAK2JAK1 | |
| SCHEMBL1368411 | 0.84 | SYK (0.42) | SYKJAK3JAK2JAK1 | |
| SCHEMBL1371147 | 0.84 | JAK3 (0.36) | SYKJAK3JAK2JAK1 | |
| SCHEMBL1369875 | 0.83 | JAK3 (0.37) | SYKJAK3JAK2JAK1 | |
| SCHEMBL21678501 | 0.83 | MEN1 (0.48) | MAPK1JAK3JAK2 | |
| SCHEMBL31070113 | 0.83 | MEN1 (0.48) | MAPK1JAK3JAK2 | |
| SCHEMBL1369791 | 0.82 | MAP2K1 (0.41) | MAPK1SYKJAK3JAK2 | |
| SCHEMBL1369901 | 0.81 | JAK3 (0.43) | SYKJAK3JAK2JAK1 | |
| SCHEMBL1368929 | 0.81 | JAK3 (0.48) | SYKJAK3 | |
| SCHEMBL1369172 | 0.81 | JAK3 (0.43) | SYKJAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | claimed |
| WO-2011144585-A1 | PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | MAPK1 438/4885SYK 1/4885JAK3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.